Minimally important differences and severity thresholds are estimated for the PROMIS depression scales from three randomized clinical trials is a research paper published in Journal of Affective Disorders (2020). On theSindex it has a DataRank of 4.3. It has been cited 130 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.731
From this paper's citation signal
Citation Network Contribution
3.6
From 85 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
HSRD VA
Grant: I01 HX000671
NCATS NIH HHS
Grant: UL1 TR001108
HSRD VA
Grant: IK6 HX002715
RRD VA
Grant: IK2 RX000879
NCATS NIH HHS
Grant: KL2 TR002530
NCATS NIH HHS
Grant: KL2 TR001106
NIAMS NIH HHS
Grant: R01 AR064081
National Institutes of Health
Grant: 3UL1TR001108-02S1
Indiana Clinical and Translational Sciences Institute
National Institutes of Health
Grant: 5KL2TR001106-03
Indiana Clinical and Translational Sciences Institute
National Institutes of Health
Grant: 5R01AR064081-02
Responsiveness and Clinical Validity of PROMIS Pain and Depression Measures
National Institutes of Health
Grant: 5IK2RX000879-05
Measurement-Based Telehealth Care of Mild Traumatic Brain Injury
National Institutes of Health
FWCI
11.22
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 1 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 2 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 2 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 3 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 3 of Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors
Additional file 1 of Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) – protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb)
Additional file 1 of Feasibility, safety and effectiveness of prednisolone and vitamin B1, B6, and B12 in patients with post-COVID-19-syndrome (PreVitaCOV) – protocol of a randomised, double-blind, placebo-controlled multicentre trial in primary care (phase IIIb)